z-logo
Premium
Aerobic interval training in standard treatment of out‐patients with schizophrenia: a randomized controlled trial
Author(s) -
Brobakken M. F.,
Nygård M.,
Güzey I. C.,
Morken G.,
Reitan S. K.,
Heggelund J.,
Wang E.,
VedulKjelsaas E.
Publication year - 2019
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/acps.13105
Subject(s) - schizophrenia (object oriented programming) , randomized controlled trial , interval training , medicine , physical therapy , confidence interval , psychology , psychiatry , physical medicine and rehabilitation
Objective To evaluate the feasibility and effects of integrating aerobic interval training ( AIT ) in standard care of out‐patients with schizophrenia on aerobic capacity and conventional cardiovascular disease ( CVD ) risk factors. Methods Out‐patients with schizophrenia spectrum disorder were randomized to the following: 1) a training group ( TG ), performing AIT 2 day/week at the clinic with adherence support from municipal services; or 2) a control group ( CG ), given two AIT sessions and encouraged to exercise on their own. Feasibility was assessed through retention/adherence.V ˙ O 2 peakwas measured directly along with conventional CVD risk factors before and after 12 weeks. Results Of 48 out‐patients, 16/25 and 18/23 completed the TG and CG respectively. After 12 weeks,V ˙ O 2 peakwas higher (2.7 ± 4.8 ml/kg/min, P  < 0.01) in the TG compared with the CG . The TG improvedV ˙ O 2 peakby 3.1 ± 3.7 ml/kg/min ( P  < 0.01), while no change in the CG was observed. No intergroup difference in weight, body mass index ( BMI ), waist circumference, blood pressure, lipids, or glucose at posttest was observed. Weight (1.9 ± 4.0 kg, P  < 0.05) and BMI (0.5 ± 1.1 kg/m 2 , P  < 0.05) increased in the CG , with no change in the TG . Conclusion AIT , combined with adherence support, of out‐patients with schizophrenia was feasible, improvedV ˙ O 2 peak, and may be integrated in standard care. (ClinicalTrials.gov identifier: NCT 02743143).

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom